NEW YORK (GenomeWeb) – OpGen today said that it has reached a deal to acquire molecular diagnostics company AdvanDx for an undisclosed amount. 

The company also announced a $6 million financing with Merck Global Health Innovation Fund (Merck GHI). 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.